© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
February 12, 2021
The company plans to submit the data to the FDA and EMA for consideration of the injectable bispecific antibody's regulatory approval for the treatment of both conditions.
January 29, 2021
Low and moderate dosing shows the most potential in preventing AMD for patients with diabetes.
January 25, 2021
Patients treated with the bispecific antibody at fixed intervals of 16 weeks achieved visual acuity outcomes comparable to 8-week interval treatment of aflibercept.
January 14, 2021
Primate model studies show the procedure can be done safely and without losing eye function. Which patients may benefit first?
November 16, 2020
There was very little difference found in visual acuity whether or not anti-VEGF treatments were used.
In data presented at AAO 2020, investigators test imaged guided intravitreal aflibercept injections for sight improvements.
November 14, 2020
In data presented at AAO, investigators examine the impact of anti-VEGF injections on ocular hypertension.
November 10, 2020
A new health care pathway could be safe to implement in clinical practice.
October 16, 2020
A large population study in Taiwan found regular use of aspirin for prevention of cardiac events increased risk for age-related macular degeneration.
October 11, 2020
Cataracts, but not AMD or glaucoma, were associated with an increased risk of depressive symptoms in the elderly in a prospective long-term study.